Formulation of human antibodies for treating TNF-alpha associated disorders
First Claim
Patent Images
1. A stable liquid aqueous pharmaceutical formulation comprising(a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα
- ) antibody at a concentration of 45-105 mg/ml,(b) a polyol,(c) a polysorbate, and(d) a buffer system comprising succinate and having a pH of 4 to 8,wherein the antibody is D2E7, andwherein the formulation is suitable for subcutaneous injection.
0 Assignments
0 Petitions
Accused Products
Abstract
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
175 Citations
30 Claims
-
1. A stable liquid aqueous pharmaceutical formulation comprising
(a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα - ) antibody at a concentration of 45-105 mg/ml,
(b) a polyol, (c) a polysorbate, and (d) a buffer system comprising succinate and having a pH of 4 to 8, wherein the antibody is D2E7, and wherein the formulation is suitable for subcutaneous injection. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)
- ) antibody at a concentration of 45-105 mg/ml,
Specification